Increased levels of plasma CXC-Chemokine Ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension

Heart and Lung: Journal of Acute and Critical Care

Volumn 43, Issue 4, 2014, Pages 322-327

  Yang, Tao ^a   Li, Zhen Nan ^a   Chen, Guo ^a   Gu, Qing ^a   Ni, Xin Hai ^a   Zhao, Zhi Hui ^a   Ye, Jue ^a   Meng, Xian Min ^a   Liu, Zhi Hong ^a   Xiong, Chang Ming ^a   He, Jian Guo ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Biomarkers; CXC chemokine ligand; Pulmonary arterial hypertension; Right ventricular function

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; CXCL16 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; STROMAL CELL DERIVED FACTOR 1;

ADULT; ARTICLE; BREATHING FREQUENCY MONITOR; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; IMAGING SOFTWARE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION; VENOUS OXYGEN TENSION;

BIOMARKERS; CXC-CHEMOKINE LIGAND; PULMONARY ARTERIAL HYPERTENSION; RIGHT VENTRICULAR FUNCTION;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; CHEMOKINE CXCL12; CHEMOKINES, CXC; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RECEPTORS, SCAVENGER; STROKE VOLUME; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR FUNCTION, RIGHT;

EID: 84903552119     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2014.04.016     Document Type: Article

References (33)

1. Galiè N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537. ESC Committee for Practice Guidelines (CPG).
2. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43:13S-24S.
3. Perros F., Dorfmüller P., Montani D., et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 185:311-321.
4. von Haehling S., von Bardeleben R.S., Kramm T., et al. Inflammation in right right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 2010, 144(2):206-211.
5. Heath D., Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. JClin Pathol 1991, 44:1003-1006.
6. Humbert M., Monti G., Brenot F., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995, 151:1628-1631.
7. Itoh T., Nagaya N., Ishibashi-Ueda H., et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006, 11:158-163.
8. Soon E., Holmes A.M., Treacy C.M., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010, 122:920-927.
9. Farber J.M. Mig and IP-10: CXC chemokines that target lymphocytes. JLeukoc Biol 1997, 61:246-257.
10. Heresi G.A., Aytekin M., Newman J., et al. CXC-Chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung 2010, 188:191-197.
11. Young K.C., Torres E., Hatzistergos K.E., et al. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res 2009, 104:1293-1301.
12. Yu L., Charles A. Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats. Respir Res 2011, 12:21.
13. Diegelmann J., Seiderer J., Niess J.H., et al. Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation. Inflamm Bowel Dis 2010, 11:1871-1881.
14. Huang M., Han Y., Zhang X., et al. An intron polymorphism in the CXCL16 gene is associated with increased risk of coronary artery disease in Chinese Han population: a large angiography-based study. Atherosclerosis 2010, 210(1):160-165.
15. Dahl C.P., Husberg C., Gullestad L., et al. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Circ Heart Fail 2009, 2:624-632.
16. Lasagni L., Francalanci M., Annunziato F., et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. JExp Med 2003, 197:1537-1549.
17. Luster A.D., Greenberg S.M., Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. JExp Med 1995, 182:219-231.
18. Bodnar R.J., Yates C.C., Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res 2006, 98:617-625.
19. Tuder R.M., Groves B., Badesch D.B., et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144:275-285.
20. Masri F.A., Anand-Apte B., Vasanji A., et al. Definitive evidence of fundamental and inherent alteration in the phenotype of primary pulmonary hypertension endothelial cells in angiogenesis. Chest 2005, 128:571S.
21. White F.C., Nakatani Y., Nimmo L., et al. Compensatory angiogenesis during progressive right ventricular hypertrophy. Am J Cardiovasc Pathol 1992, 4(1):51-68.
22. Schermuly R.T., Yilmaz H., Ghofrani H.A., et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 2005, 172(3):358-363.
23. Roeleveld R.J., Vonk-Noordegraaf A., Marcus J.T., et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 2004, 125(2):572-579.
24. Zou Y.R., Kottmann A.H., Kuroda M., et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
25. Ratajczak M.Z., Majka M., Kucia M., et al. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells 2003, 21:363-371.
26. Damås J.K., Eiken H.G., Oie E., et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000, 47:778-787.
27. Hatch H., Zheng D., Jorgensen M., et al. SDF-1 alpha/CXCR4: a mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injured liver of rats. Cloning Stem Cells 2002, 4:339-351.
28. Moore M., Hattori K., Heissig B., et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001, 938:36-45.
29. Hristov M., Zernecke A., Bidzhekov K., et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007, 100:590-597.
30. Schober A., Knarren S., Lietz M., et al. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 2003, 108:2491-2497.
31. Barbero S., Bonavia R., Bajetto A., et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003, 63:1969-1974.
32. Buckley C.D., Amft N., Bradfield P.F., et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. JImmunol 2000, 165:3423-3429.
33. Abi-Younes S., Sauty A., Mach F., et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atheroscleroticplaques. Circ Res 2000, 86:131-138.